Who are GST-HG131's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PK101-002, ZX-7101A for oral suspension, WX-0593 Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gst-hg131.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

GST-HG131 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GST-HG131 (GST-HG131) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIF-1α inhibitor. Area: Oncology.

phase 2 HIF-1α inhibitor HIF-1α Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GST-HG131 (GST-HG131) — Fujian Akeylink Biotechnology Co., Ltd.. GST-HG131 is a small molecule targeting the HIF-1α pathway.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GST-HG131 TARGET	GST-HG131	Fujian Akeylink Biotechnology Co., Ltd.	phase 2	HIF-1α inhibitor	HIF-1α
PK101-002	PK101-002	PMG Pharm Co., Ltd	phase 3	HIF-1α inhibitor	HIF-1α
ZX-7101A for oral suspension	ZX-7101A for oral suspension	Nanjing Zenshine Pharmaceuticals	phase 3	HIF-1α inhibitor	HIF-1α
WX-0593 Tablets	WX-0593 Tablets	Qilu Pharmaceutical Co., Ltd.	phase 3	HIF-1α inhibitor	HIF-1α

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIF-1α inhibitor class)

Boryung Pharmaceutical Co., Ltd · 1 drug in this class
Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
Nanjing Zenshine Pharmaceuticals · 1 drug in this class
PMG Pharm Co., Ltd · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GST-HG131 — Competitive Intelligence Brief. https://druglandscape.com/ci/gst-hg131. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing